Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-05-31
2004-11-30
LeGuyader, John L. (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S024300, C536S024330, C435S006120, C435S375000
Reexamination Certificate
active
06825337
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides compositions and methods for modulating the expression of PLML. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding PLML. Such compounds have been shown to modulate the expression of PLML.
BACKGROUND OF THE INVENTION
Despite the relatively constant osmolarity in mammals, volume-regulatory transporters have important roles in mammalian physiology because changes in cell volume also serve to signal cell growth and differentiation (O'Neill,
Am. J. Physiol
., 1999, 276, C995-C1011). An increase in cell volume in mammals is the signal for activation of chloride currents mediated by volume-activated chloride channels (Nilius et al.,
Gen. Pharmacol
., 1996, 27, 1131-1140).
One such chloride channel is phospholemman, a small transmembrane protein first discovered in canine cardiac sarcolemmal vesicles in 1991 (Palmer et al.,
J. Biol. Chem
., 1991, 266, 11126-11130). Human phospholemman has since been found to be widely distributed in human tissues with the highest expression in skeletal muscle and heart, suggesting a functional role in muscle contraction (Chen et al.,
Genomics
, 1997, 41, 435-443). Phospholemman's role as a chloride channel was suggested following the observation that phospholemman expression in Xenopus oocytes induces a chloride-selective current (Moorman et al.,
J. Biol. Chem
., 1992, 267, 14551-14554).
Shortly thereafter, a protein with a sequence related to phospholemman was discovered in murine mammary tumors whose expression is initiated by the transgenic oncogenes c-neu and v-Ha-Ras but not c-myc (Morrison and Leder,
Oncogene
, 1994, 9, 3417-3426). Subsequently, this phospholemman-like protein was found to be expressed in human breast tumors and, like phospholemman, can induce chloride conductance when expressed in Xenopus oocytes. This indicates a role for the phospholemman-like protein in regulation of chloride flux as a chloride channel or channel regulator (Morrison et al.,
J. Biol. Chem
., 1995, 270, 2176-2182).
The phospholemman-like protein expressed in breast tumors (PLML) is also known as mat-8 (mammary tumor, 8 KDa). In addition, it was recently named FXYD3 to highlight its classification as a member of the FXYD gene family of small ion transport channels or regulators named in recognition of the invariant amino acid residues Phe-X-Tyr-Asp in the signature motif (Sweadner and Rael,
Genomics
, 2000, 68, 41-56).
Since PLML is a marker specific for tumor cells transformed by Neu or Ras, it may be a required component for Neu and Ras transformation and its expression and function critical for maintenance of the transformed state (Morrison and Leder,
Oncogene
, 1994, 9, 3417-3426; Morrison et al.,
J. Biol. Chem
., 1995, 270, 2176-2182). If PLML function is found to be a critical component of certain classes of oncogenic events, it may prove to be an ideal target for therapeutic intervention in treatment of breast cancer because it is clear that PLML is not expressed by all cell types and thus does not perform a housekeeping function common to all cells (Morrison et al.,
J. Biol. Chem
., 1995, 270, 2176-2182).
The DNA sequence encoding mat-8 (PLML) is disclosed in U.S. Pat. No. 5,728,597 as are methods of detecting and treating breast cancer (Morrison and Leder, 1998).
Antisense technology is emerging as an effective means of reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic and research applications involving modulation of PLML expression.
The present invention provides compositions and methods for modulating the expression of PLML.
SUMMARY OF THE INVENTION
The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted to a nucleic acid encoding PLML, and which modulate the expression of PLML. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of modulating the expression of PLML in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of PLML by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.
REFERENCES:
patent: 5728579 (1998-03-01), Morrison et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5919655 (1999-07-01), Bandman et al.
patent: 6596490 (2003-07-01), Dattagupta
J Moran et al.,Biochimica et Biophysica Acta,“Reduction of phospholemman expression decreases osmosensitive taurine efflux in astrocyes,” 2001, 1538, pp. 313-320.*
BW Morrison et al., Journal of Biological Chemistry,“Mat-8, a Novel Phospholemman-like Protein Expressed in Human Breast Tumors, Induces a Chloride Conductance in Xenopus Oocytes,” 1995, vol. 270, No. 5, pp. 2176-2182.*
H Fritz et al.,Journal of Colloid and Interface Science,“Cationic Polystyrene Nanoparticles: Preparation and Characterization of a Model Drug Carrier System for Antisense Oligonucleotides,”1997, 195, pp. 272-288.*
Chen et al.,Characterization of the human and rat phospholemman(PLM)cDNAs and localization of the human PLM gene to chromosome 19q13.1, Genomics, 1997,41:435-443.
Moorman et al.,Phospholemman expression induces a hyperpolarization-activated chloride current in Xenopus oocytes, J. Biol. Chem., 1992,267:14551-14554.
Morrison et al.,neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors, Oncogene, 1994,9:3417-3426.
Morrison et al.,Mat-8, a novel phospholemman-like protein expressed in human breast tumors, induces a chloride conductance in Xenopus oocytes, J. Biol. Chem., 1995,270:2176-2182.
Nilius et al.,Volume-activated C1- channels, Gen. Pharmacol., 1996,27:1131-1140.
O'Neill,Physiological significance of volume-regulatory transporters, Am. J. Physiol., 1999,276:C995-C1011.
Palmer et al.,Purification and complete sequence determination of the major plasma membrane substrate for cAMP-dependent protein kinase and protein kinase C in myocardium, J .Biol. Chem., 1991,266:11126-11130.
Sweadner et al.,The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression, Genomics, 2000,68:41-56.
Gibbs Terra C.
ISIS Pharmaceuticals Inc.
LeGuyader John L.
Licata & Tyrrell P.C.
LandOfFree
Antisense modulation of PLML expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of PLML expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of PLML expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3308019